Addiction medicine ethics: relapse, no lapse and the struggle to treat addicts like everyone else

Douglas, Charles

doi:10.1111/imj.13559

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The response rate was strikingly similar to Checkmate 067 at 57%. 29 There is currently a larger randomised phase III trial underway looking at the two dosing schedules of nivolumab 1 mg/kg and ipilimumab 3 mg/kg versus nivolumab 3 mg/kg and ipilimumab 1 mg/kg to see if using the lower dose of ipilimumab will maintain response with less toxicity.…”

Section: Combination Immunotherapymentioning

confidence: 99%

Recent advances in malignant melanoma

Atkinson

2017

Internal Medicine Journal

View full text Add to dashboard Cite

In Australia, there is a high incidence of melanoma, and until recently, the treatment and median overall survival for advanced metastatic melanoma had not changed in decades. The recognition of BRAF as an important tumour oncogene in melanoma has led to the development of targeted therapies, and in the last few years, we have seen the impact of these therapies, with significant improvement in response rate, duration of disease control and overall survival for patients with BRAF mutation-positive metastatic melanoma. Concurrently, the science of immunotherapy has evolved beyond the knowledge of the importance of the immune system in cancer, leading to the development of checkpoint inhibitors. The development of checkpoint inhibitors as a tolerable and effective therapy for metastatic melanoma, which has demonstrated improved response rates, duration of control and overall survival for patients, has implications beyond the care of patients with metastatic melanoma as these therapies are being trialled in other malignancies. This article will review the current standard of care and available therapies for metastatic malignant melanoma.

show abstract

Section: Combination Immunotherapymentioning

confidence: 99%